Novel therapies to enhance patient lives
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing, and providing novel small-molecule drugs that significantly improve the lives of patients with hematologic disorders and cancer. Rigel's commercial products include TAVALISSE (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia, REZLIDHIA (olutasidenib) for relapsed or refractory acute myeloid leukemia with IDH1 mutations, and Gavreto (pralsetinib) for certain RET-altered non-small cell lung cancers. The company is headquartered in South San Francisco, California.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountOct 2019
May 2011
Jan 2002
Nov 2000
Create a free account to see which investors have funded this company.
Create Free Account
BridgeBio Pharma is a clinical-stage biopharmaceutical company developing therapies for genetic d...
R&D company with 6 SBIR/STTR awards from Department of Health and Human Services.
Biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases
Health insurance company using technology to make health care simple, affordable, and accessible.
Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...
Outpatient mental health provider offering in-person and virtual therapy, psychiatry, and psychol...
